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SUMMARY 
 
Background: Atherosclerosis is a progressive inflammatory disease and is the main underlying mechanism of cor-
onary artery disease (CAD). Immune system cells and cytokines play pivotal roles in the development of athero-
sclerosis. Several studies have shown the role of microRNA in the inflammatory processes of atherosclerosis, and 
miR-342-5p has been shown to be involved in macrophage activation during atherosclerosis and cytokine secre-
tion. But until now, there has been no data regarding the association of miR-342-5p with CAD and inflammatory 
cytokines. 
Methods: This case control study was conducted on 82 CAD patients and 80 controls. Peripheral blood mononu-
clear cell (PBMC) miR-342-5p expression and gene expression of IL-6 and TNF-α were evaluated using real time-
PCR. Also, the serum levels of IL-6 and TNF-α were measured using ELISA kits. 
Results: The results demonstrated a higher expression of miR-342-5p in CAD patients compared to controls          
(p < 0.001). Moreover, logistic regression revealed an increased risk of CAD according to the expression of miR-
342-5p after adjusting for CAD risk factors (OR [CI] = 6.1 [1.0 - 37.2], p = 0.048). Also, serum IL-6 and TNF-α 
showed higher levels in CAD patients (p = 0.003 and p = 0.004, respectively). Furthermore, there were positive 
correlations of miR-342-5p with gene expressions and serum levels of IL-6 and TNF-α. 
Conclusions: The present study demonstrated higher levels of miR-342-5p in CAD patients and showed positive 
correlation with inflammatory cytokines. This result is in accordance with a previous study, and suggested a regu-
latory role for miR-342-5p in atherosclerosis and cytokine secretion, although more studies are required in this 
direction. 
(Clin. Lab. 2018;64:603-609. DOI: 10.7754/Clin.Lab.2017.171208) 
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INTRODUCTION 
 
Coronary artery disease (CAD) is one of the most com-
mon forms of cardiovascular disease (CVD), the leading 
cause of death globally, and is characterized by athero-
sclerosis in coronary arteries [1-3]. Lifestyle, environ-
mental factors and genetic predisposition are directly in-
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volved in CAD pathogenesis [4]. Indeed, the heritability 
of CAD has been estimated to be between 40 and 60% 
[5]. Importantly, the majority of signals for CAD identi-
fied by the genome-wide association study (GWAS) ap-
proach resided in the noncoding regions of the genome 
[4]. 
MicroRNAs (miRNAs, miR) are a non-coding single 
stranded RNA (containing about 22 nucleotides) that 
regulate the expression of a wide variety of target genes 
through binding to the 3' UTR of the mRNAs [6]. Also, 
several studies have shown the dysregulation of micro-
RNA expression in the context of cardiovascular dis-
ease. Some microRNA have been suggested as diagnos-
tic tools for cardiovascular diseases [7]. 
It has been reported that they are involved in many as-
pects of atherosclerosis progression including endotheli-
al dysfunction, infiltration of inflammatory cells, low-
density lipoprotein oxidation, and CAD-associated dys-
lipidemia [8]. Studies have shown the important role of 
microRNAs in the inflammatory aspect of atherosclero-
sis, for instance miR-155 plays a role in the inflamma-
tory process and atherosclerosis [9]. Furthermore, a 
study showed that miR-342-5p promotes the production 
of inflammatory mediators and it has been suggested 
that it plays a role in atherosclerosis and was found to 
be one of the highly upregulated microRNA in early 
macrophage-rich lesions [10]. Studies have shown that 
miR-342-5p played a role in tumorigenesis and angio-
genesis [11,12], but there is no data on the expression of 
miR-342-5p in CAD patients and its association with 
inflammatory cytokines and metabolic variables. There-
fore, the present study aimed to evaluate the expression 
of miR-342-5p in CAD patients, controls and its associ-
ation with inflammatory cytokines. 
 
 
MATERIALS AND METHODS 
 
Study population 
The study population consisted of 162 Iranian individu-
als who underwent coronary angiography at the Hazrate 
Rasool Hospital, Iran University of Medical Sciences, 
Iran. The age and gender matched 82 CAD patients and 
80 non-CAD (controls) were enrolled between April 
2016 to February 2017. 
All patients underwent coronary angiography to evalu-
ate CAD. Patients with a history or evidence of diabe-
tes, cancer, renal impairment or liver disease, or any 
other chronic illnesses were excluded. The diagnosis of 
CAD was based on typical coronary angiography. All 
angiograms were evaluated by a cardiologist, and, in 
this regard, CAD was defined as the presence of steno-
sis > 50% in at least one major coronary artery [13]. 
Moreover, the controls had normal coronary arteries 
(stenosis less than 5%). The medical history, drug con-
sumption, and demographic data of the study population 
were collected on a questionnaire. The blood pressure, 
weight, and height were also recorded. Ethics approval 
was obtained from the research ethics committee of Iran 
University of Medical Sciences, and written informed 
consent was obtained from all participants in accor-
dance with the Declaration of Helsinki (IR.IUMS.REC 
1395.9221184201). 
 
Biochemical parameter measurements 
Blood samples were collected after 12 hours of fasting. 
The cholesterol, triglyceride, HDL-cholesterol, LDL-
cholesterol, and fasting blood glucose levels were mea-
sured using aliquots of serum samples stored at -80°C 
until testing, using the standard enzymatic methods. In 
addition, TNF-α and IL-6 serum levels were evaluated 
using the human cytokine ELISA kits (International 
GmbH, IBL) according to the manufacturer’s instruc-
tions. 
 
PBMCs isolation and RNA extraction 
PBMCs were isolated from 10 mL EDTA-containing 
whole blood tubes using Ficoll-Hypaque density-gradi-
ent centrifugation as previously described [14,15]. Sub-
sequently, total RNA was extracted from the PBMC ly-
sates using the miRNeasy mini kit (QIAGEN, USA) ac-
cording to manufacturer’s instructions. The concentra-
tion and purity of extracted RNA were evaluated by the 
NanoDrop spectrophotometer. 
 
Quantitation of IL-6 and TNF-α mRNA 
First-strand cDNA was synthesized from 300 ng of total 
RNA using cDNA synthesis kit (Takara, Japan). Real-
time PCR was performed using SYBR Premix Ex Taq 
II (Takara, Japan) and specific primers for IL-6 and 
TNF-α and beta-actin (QIAGEN, USA) in duplicate, ac-
cording to the standard program on ABI-StepOne (Ap-
plied Biosystems, USA). The fold change was calculat-
ed using the 2-∆∆Ct method, normalized to beta-actin. 
 
First strand cDNA synthesis and miRNAs expression 
profiling 
First-strand cDNA was synthesized from 300 ng of total 
RNA using miScript II RT Kit (QIAGEN, Germany). 
Quantitative Real Time-PCR was done using miScript 
SYBR® Green PCR Ki (QIAGEN, Germany) and spe-
cific primers for miR-342-5p and U6 (QIAGEN, USA). 
PCR amplification was carried out by use of ABI-Step-
One (Applied Biosystems USA). The expression level 
of miRNA was determined using 2-∆∆Ct and normalized 
to U6snRNA. 
 
Statistical analysis 
All statistical analyses were performed by SPSS Statis-
tical Software Package (version 18.0). Normality was 
evaluated by the Shapiro-Wilk test. Categorical data 
were shown as frequencies and continuous data were 
shown as mean ± standard error of mean (SEM). De-
pending on the normality of the data, Student’s t-test 
and Mann Whitney U test were carried out to compare 
continuous data between groups. Moreover, Pearson’s 
correlation analysis was carried out to determine the 
correlation of miRNA expressions with biochemical pa-
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rameters. Also, analysis of covariance (ANCOVA) was 
carried out to remove the possible effect of covariance 
on the expression of microRNA. Furthermore, binary 
logistic regression was performed to assess the risk of 
CAD, according to the expression of microRNA. p-val-
ues less than 0.05 were considered to be statistically 
significant. 
 
 
RESULTS 
 
Basic characteristics of the study population 
The clinical and biochemical features of a total of       
162 participants are presented in Table 1. As shown, 
CAD patients showed higher levels of BMI (p = 0.014) 
compared to non-CAD subjects. There were no statisti-
cally significant differences between CAD cases and 
normal subjects in terms of gender (p = 0.438), age       
(p = 0.091), FBS (p = 0.263), SBP (p = 0.919), DBP     
(p = 0.649), total cholesterol (p = 0.331), LDL-choles-
terol (p = 0.803), and TG (p = 0.065) levels. Moreover, 
the controls had significantly higher levels for HDL-
cholesterol (p < 0.001) than the CAD patients. 
 
Analysis of miR-342-5p expression 
Analysis of miR-342-5p expression in PBMCs revealed 
higher expression of miR-342-5p in CAD patients com-
pared to controls (p < 0.001) (Figure 1A). In addition, 
ANCOVA was performed to remove the effect of age, 
gender, and BMI on the expression of miR-342-5p, and 
after adjustment the difference remained significant      
(p = 0.001). Also, binary logistic regression demon-
strated a significant relationship between miR-342-5p 
and the presence of CAD (OR [CI] = 8.8 [2.2 - 35.7],     
p = 0.002), and after adjusting for classical CAD risk 
factor, it was found that miR-342-5p is significantly as-
sociated with the risk of CAD presence (OR [CI] = 6.1 
[1.0 - 37.2], p = 0.048) (Table 2). Also, the ROC curve 
was plotted to assess the ability of miR-342-5p expres-
sion for the diagnosis of CAD. The result of this study 
demonstrated that the area under curve was 0.702        
(CI = 0.620 - 0.783, p < 0.001) (Figure 2). 
 
Comparison of cytokine levels between CAD pa-
tients and controls 
The results revealed that TNF-α (p = 0.004) and IL-6     
(p = 0.003) gene expression in PBMCs was significantly 
higher in CAD patients compared to controls (Figure 
1B and Figure 1C). Furthermore, TNF-α demonstrated 
higher serum levels in CAD patients (12.69                    
± 1.12 pg/mL) compared to controls (8.78                       
± 0.52 pg/mL) (p = 0.002) (Figure 2A). Likewise, the 
IL-6 serum levels were found to be higher in CAD pa-
tients (6.45 ± 0.31 pg/mL) compared to controls (5.44     
± 0.31 pg/mL) (p = 0.023) (Figure 2B). 
 
Association of miR-342-5p with molecular and bio-
chemical parameters 
The correlation of miR-342-5p and molecular, biochem-
ical, and anthropometrical parameters were determined 
using Pearson’s correlation analysis. The results are 
presented in Table 3. Correlation analysis in controls 
showed inverse correlation of miR-342-5p with DBP 
and HDL-C. Furthermore, miR-342-5p was found to be 
positively correlated with LDL-C, TNF-α, and IL-6 
gene expressions as well as TNF-α and IL-6 serum lev-
els. Also, the analysis of correlations in CAD patients 
showed inverse correlation between miR-342-5p and 
HDL-C. Moreover, miR-342-5p was found to be posi-
tively correlated with TNF-α and IL-6 gene expressions 
as well as TNF-α and IL-6 serum concentration. 
 
 
DISCUSSION 
 
Inflammation plays a substantial role in the develop-
ment of atherosclerosis and regulation of inflammatory 
signaling and cytokines secretion that could be a poten-
tial therapeutic target for atherosclerosis and CAD [16]. 
Several studies have shown the association of micro-
RNA with the feature of atherosclerosis. Some of them 
have been suggested as potential biomarkers for CAD, 
especially myocardial infarction [17]. Although, several 
microRNA have been studied in the context of CAD 
and atherosclerosis [18,19], only one study has evalu-
ated the role of miR-342-5p in the pathogenesis of ath-
erosclerosis in animal model and cell line [10]. The 
present study evaluated miR-342-5p as a new regulatory 
factor for macrophage activation in atherosclerosis [20]. 
The present findings demonstrated that the PBMC ex-
pressions of miR-342-5p was higher in CAD patients 
than in control subjects. This result was independent of 
age, gender and BMI. Also, miR-342-5p showed a rela-
tionship with CAD, independent from the classical risk 
factors for CAD. Two studies evaluated the role of miR-
342-5p in cancer tumorigenesis and angiogenesis [11, 
12]. One study has reported a role for miR-342-5p in 
the development of atherosclerosis in an animal model 
[10]. However, to the best of our knowledge, the present 
study is the first in vivo report regarding the association 
of miR-342-5p with CAD. 
Yuanyuan et al. reported miR-342-5p as highly upregu-
lated in macrophage-rich lesions. It also suggested that 
miR-342-5p plays a role in macrophage activity during 
atherosclerosis [10]. In line with this result, the findings 
of the present study demonstrated a higher expression of 
miR-342-5p in the PBMCs of CAD patients. PBMCs 
include mononuclear cells of the immune system that 
are involved in the development of atherosclerosis. 
Monocytes, as a part of PBMCs, infiltrate into the arte-
rial wall during atherosclerosis and differentiate to mac-
rophages which uptake Ox-LDL. The upregulation of 
miR-342-5p might increase the inflammatory response 
during atherosclerosis, although more studies are need-
ed to prove this concept. 
Also, it has been shown that miR-342-5p promotes the 
synthesis of inflammatory mediators such as NOS2 and 
CCL2 [10]. Moreover, the miR-342-5p inhibitor re-
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Table 1. Anthropometric and laboratory measurement of study population. 
 
Parameter Controls (n = 80) 
CAD patients 
(n = 82) p 
Gender (male/female) 41/39 35/47 0.438 
Age (years) 57.86 ± 0.97 60.10 ± 0.89 0.091 
Body mass index (kg/m2) 26.14 ± 0.49 27.56 ± 0.47 0.014 
Systolic blood pressure (mmHg) 129.8 ± 2.1 132.7 ± 3.3 0.919 
Diastolic blood pressure (mmHg) 82.06 ± 1.40 82.13 ± 1.80 0.649 
Fasting blood sugar (mg/dL) 92.54 ± 1.11 93.93 ± 1.22 0.263 
LDL-Cholesterol (mg/dL) 75.73 ± 3.34 74.56 ± 2.82 0.803 
HDL-Cholesterol (mg/dL) 44.93 ± 0.98 39.11 ± 1.02 < 0.001 
Triglycerides (mg/dL) 131.2 ± 5.36 139.8 ± 4.57 0.065 
Total Cholesterol (mg/dL) 134.7 ± 3.1 139.1 ± 3.2 0.331 
 
 
 
 
Table 2. Odds ratios of CAD incidents according to miR-342 expression in PBMCs. 
 
Model B S.E. OR 95% C.I. for OR p 
1 2.172 0.716 8.8 2.1 - 35.7 0.002 
2 1.815 0.919 6.1 1.0 - 37.2 0.048 
 
Model 1 - Crude model. 
Model 2 - Adjusted for age, gender, BMI, smoking, SBP, DBP, Chol, HDL-C, LDL-C, IL-6, TNF-α. 
 
 
 
 
Table 3. Correlation analysis of miR-342 with anthropometric, laboratory, and molecular data. 
 
 
Controls CAD 
Correlation 
coefficient Sig. (2-tailed) 
Correlation 
coefficient Sig. (2-tailed) 
Age (years) -0.144 0.204 -0.005 0.966 
Systolic blood pressure(mmHg) -0.218 0.052 -0.127 0.257 
Diastolic blood pressure (mmHg) -0.264 0.018 -0.058 0.604 
Body mass index (kg/m2) -0.178 0.114 0.184 0.098 
Fasting blood sugar (mg/dL) -0.067 0.557 -0.111 0.320 
Triglycerides (mg/dL) -0.194 0.085 -0.070 0.533 
Total Cholestrol (mg/dL) 0.194 0.085 0.003 0.979 
LDL-Cholestrol (mg/dL) 0.357 0.001 0.109 0.331 
HDL-Cholestrol (mg/dL) -0.282 0.011 -0.233 0.035 
TNF-Expression 0.257 0.021 0.220 0.047 
IL6-Expression 0.0.260 0.020 0.416 0.000 
TNF-α (pg/mL) 0.305 0.006 0.303 0.006 
IL-6 (pg/mL) 0.233 0.038 0.503 0.000 
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Figure 1. miR-342-5p expression and gene expressions of TNF-α and IL-6 in PBMCs. 
 
A) miR-342-p5 showed higher expression in CAD group (p = 0.001). B) TNF-α gene expression in PBMCs was found to be higher in CAD 
patients (p = 0.003). C) IL-6 gene expression in PBMCs of CAD patients was higher than controls (p = 0.004). 
 
 
 
 
 
 
 
 
 
 
Figure 2. ROC curve for diagnosis of CAD. 
 
 
 
 
duced IL-6 and TNF-α expression [10]. In line with this 
result, the positive correlation of miR-342-5p expres-
sion with IL-6 and TNF-α gene expressions and serum 
levels was detected. The result of the present study is an 
in vivo evidence for the association of miR-342-5p with 
inflammation that could be a possible underlying mech-
anism for the association of miR-342-5p with CAD.   
miR-342-5p was found to be positively associated with 
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Figure 3. Serum concentration of cytokines. 
 
A) Serum levels of TNF-α showed higher levels in CAD group (p = 0.002). B) IL-6 serum concentration was found to be higher in CAD group 
(p = 0.028). 
 
 
 
LDL-C and negatively associated with HDL-C. A previ-
ous study showed that highly oxidized LDL upregulated 
the expression of miR-342-5p [10]. This result suggest-
ed a possible relationship between miR-342-5p and li-
poprotein metabolism; however, further studies are 
needed to detect a possible underlying mechanism.           
Taken together, the results obtained serve as in vivo evi-
dence for the relationship of miR-342-5p with CAD and 
inflammatory cytokines and is in line with a previous 
study by Yuanyuan et al. that suggested a role for miR-
342-5p in atherosclerosis by promoting the expression 
of L-6 and TNF-α [10]. 
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